Achieve Life Sciences, Inc. QUIT
Biotechnology: In Vitro & In Vivo Diagnostic Substances · data as of November 13, 2026
Achieve Life Sciences, Inc. (QUIT) is a healthcare company listed in the US with a market value of about $695M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
About Achieve Life Sciences
Achieve Life Sciences is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances. It was profitable in 0 of the last 10 years in our data. Its share count rose by 312% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 | — | — |
| Net income | -$55M | -$40M | -$30M | -$42M | -$33M | -$15M | -$16M | -$13M | -$11M | -$1M |
| Free cash flow | -$49M | — | -$24M | — | — | -$13M | -$15M | -$11M | — | -$248000 |
| EPS (diluted) | $-1.25 | $-1.24 | $-1.50 | $-4.00 | $-4.08 | $-5.42 | $-39.76 | $-72.29 | $-441.40 | $-11625.00 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | — | — | — | — | — | — | -70.9% | -64.0% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $14.58, 131% above the current price; targets range from $10.00 to $21.00; the consensus rating is “Strong buy”; expected EPS is $-1.34 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Achieve Life Sciences pay a dividend?
Not currently.
Is Achieve Life Sciences a good stock to buy?
We do not give buy or sell advice. Achieve Life Sciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.